Posts

Protecting Your Heart During Hormone Therapy:

Image
IMPACT-ADT: Mitigating Cardiovascular Risks in Prostate Cancer Care - YouTube New Research Offers Hope BLUF (Bottom Line Up Front) A groundbreaking clinical trial at City of Hope is testing whether intermittent fasting or GLP-1 medications (like Ozempic) can protect prostate cancer patients from the cardiovascular risks of androgen deprivation therapy (ADT). This American Heart Association-funded study addresses a critical gap: most heart attacks in ADT patients occur within the first six months of treatment—before significant metabolic changes appear—suggesting an urgent need for early protective interventions. [See Sidebar: "Understanding Your Personal Risk Balance" for detailed analysis of when cardiovascular risk may outweigh cancer risk in your specific situation] The Cardiovascular Risk of Hormone Therapy When you start ADT for prostate cancer, your oncologist focuses on controlling your cancer. But cardiovascular disease represents a significant concurrent risk th...
Post a Comment
Read more

IPCSG Monthly News: Prostate Cancer Care Achievements

Image
UC San Diego Prostate Cancer Patient Summit 2026 - Summary No IPCSG Meeting in January, Members Were Encouraged to Attend this Instead.  Event Details: Date: January 30-31, 2026 Location: UC San Diego Attendance: Over 200 patients, caregivers, advocates, and healthcare professionals Day One (January 30, 2026) Community Think Tank Patient and caregiver-led roundtable discussions Focus areas: care gaps, unanswered questions, treatment and support futures Led by: Dr. Rana McKay (Professor of Medicine, Urology, and Radiation Medicine and Applied Sciences) Dr. Christina Jamieson (Associate Professor in Residence, Urology) Dr. Chris Kane (Urologist, CEO of UC San Diego Health Physician Group) "Big Questions in the Field" Panel Direct engagement between leading clinicians and community members Dynamic dialogue honoring patient experiences while sharing latest care advances Conclusion: Large group discussion and action plan development Day Two (January 31, 2026) Openin...
Post a Comment
Read more

IPCSG News Prostate Cancer Care: 2025 Year in Review

Image
Breakthrough Achievements and Transformative Developments Annual Report for the Informed Prostate Cancer Support Group (IPCSG) By Claude AI Anthropic, February 13, 2026 Executive Summary The year 2025 represented a watershed moment in prostate cancer care, marked by unprecedented advances across the treatment continuum—from early detection through metastatic disease management. Major FDA approvals expanded access to PSMA-targeted therapies and precision medicine approaches, landmark clinical trials demonstrated substantial survival benefits with novel combination strategies, and industry consolidation positioned major pharmaceutical companies for continued innovation. This comprehensive review synthesizes the year's most significant achievements that are reshaping prostate cancer outcomes. FDA Regulatory Milestones PSMA Radioligand Therapy Expansion The most clinically significant FDA action of 2025 came in March, when the agency expanded the approved indication for luteti...
Post a Comment
Read more